Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Digoxin Dangers: A proportion of patients treated with digoxin, a cardiac glycoside used to treat heart function abnormalities, generate the inactive metabolite, dihydrodigoxin, resulting in poor efficacy. Haiser et al. (p. 295 ) examined a potential culprit responsible for this transformation—the actinobacterium, Eggerthella lenta —to probe the microbiota-digoxin interaction. Microbe growth was promoted by arginine, and differential expression analysis revealed a two-gene cardiac glycoside reductase ( cgr ) operon that was induced by digoxin in low arginine conditions. Not all strains of E. lenta could reduce digoxin and, when fecal samples from healthy people were tested, a spectrum of digoxin inactivation was detected. When the digoxin-reducing strain of E. lenta was given to germ-free mice that were fed a high-protein (that is, high-arginine) diet, digoxin levels stayed high in serum, and drug inactivation was suppressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notably, the cgr ratio could be used to effectively discriminate microbial communities exhibiting low versus high digoxin reduction (Fig. 5).”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“The amino acid arginine prevents digoxin inactivation by E. lenta in vitro, decreasing the expression and activity of the genes responsible (the cgr operon)67.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“Because the intestine is a major site for drug metabolism (both by cytochrome P-450 enzymes in intestinal epithelial cells and by the gut microbiome87)”
From Microfluidic Organ-on-a-Chip Models of Human Intestine (2018) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Haiser et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“was inducible by the drug it metabolizes (Haiser et al., 2013).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Haiser et al., 2013
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer3—new capabilities and interfaces
Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B. C., Remm, M., & Rozen, S. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,461
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Versatile and open software for comparing large genomes
Kurtz, S., Phillippy, A., Delcher, A. L., Smoot, M., Shumway, M., Antonescu, C., & Salzberg, S. L. (2004) · Genome Biology · doi:10.1186/gb-2004-5-2-r12 · Cited by 5,254
Breitling, R., Armengaud, P., Amtmann, A., & Herzyk, P. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.055 · Cited by 1,496
Isolation of a Bacterium That Reductively Dechlorinates Tetrachloroethene to Ethene
Maymó-Gatell, X., Chien, Y.-T., Gossett, J. M., & Zinder, S. H. (1997) · Science · doi:10.1126/science.276.5318.1568 · Cited by 1,125
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
SSAHA: A Fast Search Method for Large DNA Databases
Ning, Z., Cox, A. J., & Mullikin, J. C. (2001) · Genome Research · doi:10.1101/gr.194201 · Cited by 965
Xenobiotics shape the physiology and gene expression of the active human gut microbiome
Maurice, C. F., Haiser, H. J., & Turnbaugh, P. J. (2013) · Cell · doi:10.1016/j.cell.2012.10.052 · Cited by 811
A Catalog of Reference Genomes from the Human Microbiome
The Human Microbiome Jumpstart Reference Strains Consortium, Nelson, K. E., Weinstock, G. M., Highlander, S. K., Worley, K. C., Creasy, H. H., Wortman, J. R., Rusch, D. B., Mitreva, M., Sodergren, E., et al. (2010) · Science · doi:10.1126/science.1183605 · Cited by 702
Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy
Lindenbaum, J., Rund, D. G., Butler, V. P., Tse-Eng, D., & Saha, J. R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110013051403 · Cited by 423
Cited by
Items 301–400 of 704
Metabolomics in pharmacology - a delve into the novel field of pharmacometabolomics
Mussap, M., Loddo, C., Fanni, C., & Fanos, V. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1713750 · Cited by 38
Engineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities
Khan, S. M., Hauptman, R., & Kelly, L. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031620-031509 · Cited by 32
Feng, W., Liu, J., Huang, L., Tan, Y., & Peng, C. Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111047 · Cited by 37
Malwe, A. S., Srivastava, G. N., & Sharma, V. K. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168056 · Cited by 35
Activity-Based Protein Profiling—Enabling Multimodal Functional Studies of Microbial Communities
Whidbey, C., & Wright, A. (2018) · Current topics in microbiology and immunology · doi:10.1007/82_2018_128 · Cited by 31
“In fact, one of the best examples of connecting a metabolic reaction to a particular organism is the reduction of digoxin to dihydrodigoxin by the gut microbe Eggerthella lenta (Haiser et al. 2014; Haiser et al. 2013).”
BackgroundExploiting the Metabolism of the Gut Microbiome as a Vehicle for Targeted Drug Delivery to the Colon
Bakshi, H. A., Quinn, G. A., Aljabali, A. A. A., Hakkim, F. L., Farzand, R., Nasef, M. M., Abuglela, N., Ansari, P., Mishra, V. K., Serrano‐Aroca, Á., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14121211 · Cited by 34
Bhushan, B., Singh, B. P., Saini, K., Kumari, M., Tomar, S. K., & Mishra, V. (2019) · Environmental Chemistry Letters · doi:10.1007/s10311-019-00914-9 · Cited by 29
“Some specified dietary interventions and/or supplements may revert back the drug inhibitory mechanisms (Haiser et al. 2013) or support the beneficiary actions of microbiota.”
BackgroundShen, H., Tong, X., Yang, J., Yu, L., Zhou, H., Wang, Y., He, Y. T., Wan, H., & Li, C. (2020) · Food & Function · doi:10.1039/d0fo00775g · Cited by 33
Stothart, M. R., & Newman, A. E. M. (2021) · Animal Microbiome · doi:10.1186/s42523-021-00105-4 · Cited by 33
Detecting bacterial adaptation within individual microbiomes
Lieberman, T. D. (2022) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2021.0243 · Cited by 33
“While much attention has been paid to the ecology of microbiomes within individual people—which bacterial species reside within us during health [1,2], how these species interact with one another [3–5], and how they interact with the host [6,7]—relatively less attention has been paid to the evolution of single species…”
BackgroundStereoselective Synthesis of 2-Deoxy Glycosides via Iron Catalysis
Hou, M., Xiang, Y., Gao, J., Zhang, J., Wang, N., Shi, H., Huang, N., & Yao, H. Q. (2023) · Organic Letters · doi:10.1021/acs.orglett.2c04379 · Cited by 30
Moore, B. D., Wiggins, N., Marsh, K. J., Dearing, M. D., & Foley, W. J. (2015) · Animal Production Science · doi:10.1071/an14487 · Cited by 31
“For example, in gnobiotic mice, dietary protein reduced the in vivo microbial metabolism of digoxin, with significant increases in drug concentration in the serum and urine (Haiser et al. 2013).”
BackgroundActivity of GPCR-targeted drugs influenced by human gut microbiota metabolism
Wu, Q., Song, D., Zhao, Y., Verdegaal, A. A., Turocy, T., Lowey, B., Goodman, A. L., Palm, N. W., & Crawford, J. M. (2025) · Nature Chemistry · doi:10.1038/s41557-025-01789-w · Cited by 31
Relationship Between Gut Bacteria and Levodopa Metabolism
Xu, K., Sheng, S., & Zhang, F. (2022) · Current Neuropharmacology · doi:10.2174/1570159x21666221019115716 · Cited by 29
“This conversion was determined by E. lenta , which was previously reported to present its ability to para-hydroxylate DHPPA [46, 47].”
BackgroundCai, J., Auster, A., Cho, S., & Lai, Z. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.07.002 · Cited by 31
“Successful examples include the identification of the cardiac glycoside reductase ( cgr) operon in Eggerthella lenta for digoxin reduction or inactivation and the preTA operon in Escherichia coli for 5-fluorouracil inactivation [149].”
BackgroundThe Role of Gut Microbiota and Its Metabolites in Patients with Heart Failure
Cienkowski, K., Cienkowska, A., Kupczyńska, K., & Bielecka-Dabrowa, A. M. (2024) · Biomedicines · doi:10.3390/biomedicines12040894 · Cited by 31
“Some bacteria can also metabolize drugs into their inactive form, as with digoxin, which in 10% of patients is transformed by Eggerthella lenta bacteria, consequently reducing the drug’s efficacy [104].”
BackgroundPharmacokinetic and pharmacodynamic alterations in older people: what we know so far
Mangoni, A. A., Woodman, R. J., & Jarmuzewska, E. A. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2503848 · Cited by 33
Impact of occupational exposure on human microbiota
Lai, P. S., & Christiani, D. C. (2018) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000502 · Cited by 31
Camelo-Castillo, A. J., Rivera‐Caravaca, J. M., Orenes‐Piñero, E., Ramírez-Macías, I., Roldán, V., Lip, G. Y. H., & Marín, F. R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040715 · Cited by 27
“[92] identified a group of digoxin-inducible genes, only present in Eggerthellalenta strains that metabolize digoxin.”
Key Technologies for Progressing Discovery of Microbiome-Based Medicines
Young, R. B., Marcelino, V. R., Chonwerawong, M., Gulliver, E. L., & Forster, S. C. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.685935 · Cited by 30
Longitudinal Characterization of the Gut Bacterial and Fungal Communities in Yaks
Wang, Y., Fu, Y., He, Y., Kulyar, M. F., Iqbal, M., Li, K., & Liu, J. (2021) · Journal of Fungi · doi:10.3390/jof7070559 · Cited by 28
“Several microbiome members induced the development of Th17 cells, whereas other microbes contributed to regular the development of T cells and intestinal immune tolerance [17].”
BackgroundComputational tools for modeling xenometabolism of the human gut microbiota
Klünemann, M., Schmid, M., & Patil, K. R. (2014) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.01.005 · Cited by 29
Nardos, R., Leung, E. T., Dahl, E. M., Davin, S., Asquith, M. J., Gregory, W. T., & Karstens, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.759156 · Cited by 31
Anwardeen, N. R., Naja, K., & Elrayess, M. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1506767 · Cited by 33
Gut microbiome: A possible common therapeutic target for treatment of atherosclerosis and cancer
Wu, W., Ivanova, E. A., & Orekhov, A. N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.017 · Cited by 29
Next steps after 15 stimulating years of human gut microbiome research
Clavel, T., Horz, H., Segata, N., & Vehreschild, M. J. G. T. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13970 · Cited by 26
“Moreover, as gut microbes have been shown to influence drug metabolism and efficacy, microbiomebased companion diagnostics is a flourishing area of research and developments (Haiser et al., 2013; Zimmermann et al., 2019; Roberti et al., 2020).”
BackgroundColman, R. J., Mizuno, T., Fukushima, K., Haslam, D. B., Hyams, J. S., Boyle, B., Noe, J. D., D’Haens, G., Limbergen, J. V., Chun, K., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17277 · Cited by 27
Gut microbiota in toxicological risk assessment of drugs and chemicals: The need of hour
Velmurugan, G. (2018) · Gut Microbes · doi:10.1080/19490976.2018.1445955 · Cited by 27
Variation in human gut microbiota impacts tamoxifen pharmacokinetics
Alam, Y. H., Hakopian, S., de Ora, L. O., Tamburini, I. J., Avelar‐Barragan, J., Jung, S., Long, Z. G., Chao, A., Whiteson, K., Jang, C., et al. (2024) · mBio · doi:10.1128/mbio.01679-24 · Cited by 29
Inflammatory bowel disease and the gut microbiota
Wu, N., Mah, C., Koentgen, S., Zhang, L., Grimm, M., El-Omar, E. M., & Hold, G. L. (2021) · Proceedings of The Nutrition Society · doi:10.1017/s002966512100197x · Cited by 30
Baud, G., Prasad, A., Ellegaard, K., & Engel, P. (2023) · Genome biology · doi:10.1186/s13059-023-03131-4 · Cited by 29
A Molecular Perspective of Microbial Pathogenicity
Relman, D. A., & Falkow, S. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00001-1 · Cited by 29
Gut Microbiota in Heart Failure—The Role of Inflammation
Fountoulakis, P. N., Theofilis, P., Vlachakis, P. K., Karakasis, P., Pamporis, K., Sagris, Μ., Dimitroglou, Y., Tsioufis, P., Oikonomou, E. K., Tsioufis, K. P., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13040911 · Cited by 27
“In certain circumstances, the bacterium Eggerthella lenta , belonging to the Actinobacteria phylum, reduces the bioavailability of digoxin through its conversion to the inactive product, dihydrodigoxin [63].”
The impact of the human gut microbiome on the treatment of autoimmune disease
Nayak, R. R., & Orellana, D. A. (2024) · Immunological Reviews · doi:10.1111/imr.13358 · Cited by 23
Priputnevich, T. V., Lyubasovskaya, L. A., Muravieva, V. V., Kondrakhin, A. P., Игнатьева, А. Е., Gordeev, A. B., Shmakov, R. G., Sukhikh, G. T., & Львовна, Я. Е. (2019) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2019.1602602 · Cited by 40
Zhang, X., Cheng, K., Ning, Z., Mayne, J., Walker, K., Chi, H., Farnsworth, C. L., Lee, K., & Figeys, D. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c00962 · Cited by 23
Microbiome First Medicine in Health and Safety
Dietert, R. R. (2021) · Biomedicines · doi:10.3390/biomedicines9091099 · Cited by 23
Gong, X., Liu, Y., Liu, X., Li, A. Q., Guo, K., Zhou, D., & Hong, Z. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.105340 · Cited by 25
The Microbiome and Its Potential for Pharmacology
Chavira, A., Belda‐Ferre, P., Kościółek, T., Ali, F., Dorrestein, P. C., & Knight, R. D. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_317 · Cited by 22
Gut Microbiome Integration in Drug Discovery and Development of Small Molecules
Jimonet, P., Druart, C., Blanquet‐Diot, S., Boucinha, L., Kourula, S., Vacon, F. L., Maubant, S., Rabot, S., de Wiele, T. V., Schuren, F. H. J., et al. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001605 · Cited by 25
Connecting the dots: Targeting the microbiome in drug toxicity
Luo, Y., & Zhou, T. (2021) · Medicinal Research Reviews · doi:10.1002/med.21805 · Cited by 21
“The discovery of cgr in digoxin metabolism facilitates understanding of its variable toxic effects and pharmacokinetic parameters among the population(115) and offers strategies in reducing its metabolism and consequently manipulating its toxicity.(114) The series of studies concerning microbiota‐associated digoxin me…”
BackgroundMaterial Engineering in Gut Microbiome and Human Health
Yang, L., Hung, L. Y., Zhu, Y., Ding, S., Margolis, K. G., & Leong, K. W. (2022) · Research · doi:10.34133/2022/9804014 · Cited by 31
Braccia, D. J., Ndjite, G. M., Weiss, A., Levy, S., Abeysinghe, S., Jiang, X., Pop, M., & Hall, B. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.000898 · Cited by 24
Yan, X., Yao, J., Li, Y.-Q., Xiao, X., Yang, W., Chen, S.-J., Tang, T., Yang, Y.-Q., Qu, L., Hou, Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1223742 · Cited by 24
“, 2022), and drug response and development (Haiser et al., 2013).”
BackgroundMiyoshi, J., Nobutani, K., Musch, M. W., Ringus, D. L., Hubert, N. A., Yamamoto, M., Kase, Y., Nishiyama, M., & Chang, E. B. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/7415975 · Cited by 23
“Examples of this include the bacterial cytochrome encoding operon of Eggerthella lenta that metabolizes digoxin [3], bacterial glucuronidases that are responsible for the reactivation of the phase II product of the chemotherapeutic drug irinotecan [4], and bacterial glycosidases, and glucosi-dases…”
The Surviving Sepsis Campaign: Basic/Translational Science Research Priorities*
Deutschman, C. S., Hellman, J., Ferrer, R., Backer, D. D., & Coopersmith, C. M. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004408 · Cited by 21
Mechanisms of intestinal pharmacokinetic natural product-drug interactions
Oyanna, V. O., & Clarke, J. D. (2024) · Drug Metabolism Reviews · doi:10.1080/03602532.2024.2386597 · Cited by 27
“…vitamins, and potentially enhancing immunity (Gomaa 2020; Pant et al. 2023). the gut microbiota can directly influence the PK of conventional medicines by altering the metabolism of drugs such as amiodarone, digoxin, and nabumetone (Haiser et al. 2013; Yoo et al. 2016; Jourova et al. 2019).”
Microbes and medicines: interrelationships between pharmaceuticals and the gut microbiome
Al-Btoosh, S., Donnelly, R. F., & KELLY, S. C. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2604867 · Cited by 28
García, C. J., Beltrán, D., & Tomás-Barberán, F. A. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000619 · Cited by 22
The new microbiology: cultivating the future of microbiome-directed medicine
Ha, C. W. Y., & Devkota, S. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00093.2020 · Cited by 25
“Culture-based assays have shown that specific strains of Eggerthella lenta are able to inactivate the cardiac drug digoxin (63), and that dietary arginine can reduce microbial metabolism of digoxin in vivo, with consequences in drug bioavailability (22).”
BackgroundOh, H., Min, U.-G., Jang, H.-J., Kim, N., Lim, J., Chalita, M., & Chun, J. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-1526-0 · Cited by 23
“Diet and drugs are key exogenous factors that can affect the formation and structure of the host gut microbiome (Haiser et al., 2013; David et al., 2014; Rogers and Aronoff, 2016; Maier et al., 2018; Zimmermann et al., 2019).”
BackgroundThe Human Microbiota: Composition, Functions, and Therapeutic Potential
Conrad, R., & Vlassov, A. V. (2015) · Medical Science Review · doi:10.12659/msrev.895154 · Cited by 27
Arbutin ameliorated depression by inhibiting neuroinflammation and modulating intestinal flora
Cao, Y., Zhao, K., Zhao, Y., Ni, Y., Zhang, Z., Yuan, X., Ning, J., Song, Q., Zhao, F., He, L., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156944 · Cited by 21
Deciphering the universal role of gut microbiota in pollutant transformation
Hou, R., Jin, X., Feng, J., Xue, J., Chen, C., Zou, Y., Xu, X., Yu, K., Qian, P., Zhang, W., et al. (2025) · The ISME Journal · doi:10.1093/ismejo/wraf215 · Cited by 25
“Nitrazepam can be efficiently reduced to 7-aminonitrazepam by Clostridium leptum from human gut [66], whereas the cardiac drug digoxin can undergo alkene cleavage by the human gut microbiota to produce dihydrodigoxin [67].”
Effects of intestinal microbiota on pharmacokinetics of cyclosporine a in rats
Zhou, J., Zhang, R., Guo, P., Li, P., Huang, X., Ye, W., Yang, C., Zhou, J., Yang, T., Liu, Y., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1032290 · Cited by 20
Kinross, J. K., Li, J. V., Muirhead, L. J., & Nicholson, J. K. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000036 · Cited by 19
Human microbiome science: vision for the future,
Ravel, J., Blaser, M. J., Braun, J. G., Brown, E., Bushman, F. D., Chang, E. B., DAVIES, J. E., Dewey, K. G., Dinan, T. G., Domínguez-Bello, M. G., et al. (2014) · Cited by 19
Self-citationThe rising dominance of microbiology: what to expect in the next 15 years?
Kumar, R., Sood, U., Kaur, J., Anand, S., Gupta, V., Patil, K. S., & Lal, R. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13953 · Cited by 21
“A known cardiovascular drug like digoxin was found deactivated or attenuated by cardiac glycoside reductase present in Eggerthella lenta, a gut resident known from decades (Haiser et al., 2013).”
BackgroundSystematic mapping of drug metabolism by the human gut microbiomePreprint
Chankhamjon, P., Javdan, B., Lopez, J. G., Hull, R., Chatterjee, S., & Donia, M. S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/538215 · Cited by 19
Dong, Z., Yu, P., Li, J., Zhou, H., Li, R., Wang, S., Yang, G., Nie, Y., Liu, L., Bian, X., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115517 · Cited by 21
The Gut Microbiome and Its Impact on Mood and Decision-Making: A Mechanistic and Therapeutic Review
Diotaiuti, P., Misiti, F., Marotta, G., Falese, L., Calabrò, G. E., & Mancone, S. (2025) · Nutrients · doi:10.3390/nu17213350 · Cited by 27
New Horizons in Microbiota and Metabolic Health Research
Mishra, S. P., Jain, S., Taraphder, S., & Yadav, H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa769 · Cited by 19
Role of the gut microbiome in cardiovascular drug response: The potential for clinical application
Steiner, H. E., Gee, K., Giles, J. B., Knight, H., Hurwitz, B. L., & Karnes, J. H. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2650 · Cited by 22
A toxic shrub turned therapeutic: The dichotomy of Nerium oleander bioactivities
Sharma, R. K., Singh, S., Tewari, N., & Dey, P. (2023) · Toxicon · doi:10.1016/j.toxicon.2023.107047 · Cited by 21
Malwe, A. S., & Sharma, V. K. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1254073 · Cited by 27
Human gut Actinobacteria boost drug absorption by secreting P-glycoprotein ATPase inhibitors
Kyaw, T. S., Zhang, C., Sandy, M., Trepka, K. R., Zhang, S., Hernandez, L. A. R., Ramirez, L., Goh, J. J., Yu, K., DiMassa, V., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110122 · Cited by 18
“lenta increases the rate of absorption of digoxin in gnotobiotic mice, balancing out the effects of bacterial drug metabolism (Haiser et al. 2013).”
InfluentialSelf-citationEmerging tools and best practices for studying gut microbial community metabolism
Noecker, C. A., & Turnbaugh, P. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01074-z · Cited by 25
“Strain-level differences in Eggerthella lenta alter the metabolism of drugs 25,26 and dietary polyphenols 27 .”
Self-citationResources and tools for the high-throughput, multi-omic study of intestinal microbiota
Blanco‐Míguez, A., Fdez‐Riverola, F., Sánchez, B., & Lourenço, A. M. G. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx156 · Cited by 16
“…microbiome and metabolome data [26], proteome and metagenome data supported the investigation of Crohn’s disease (CD) [27] and metabolome, metagenome and metatranscriptome data provide a basis for the investigation of the relations among gut microbiome and the xenobiotic metabolism of digoxin [28].”
BackgroundChemical reaction vector embeddings: towards predicting drug metabolism in the human gut microbiome
Mallory, E. K., Acharya, A., Rensi, S., Turnbaugh, P. J., Bright, R. A., & Altman, R. B. (2017) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789813235533_0006 · Cited by 26
Self-citationGargis, A. S., McLaughlin, H. P., Conley, A. B., Lascols, C., Michel, P. A., Gee, J. E., Marston, C. K., Kolton, C. B., Rodriguez‐R, L. M., Hoffmaster, A. R., et al. (2018) · mSystems · doi:10.1128/msystems.00154-18 · Cited by 23
Bisanz, J. E., Soto-Perez, P., Lam, K. N., Bess, E. N., Haiser, H. J., Allen‐Vercoe, E., Rekdal, V. M., Balskus, E. P., & Turnbaugh, P. J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/304840 · Cited by 17
“Finally, we showed that ElenMatchR can also be readily applied to identify genes for drug metabolism as it correctly identifies the cardiac glycoside reductase (cgr) operon responsible for digoxin reduction (16) as well as an expanded loci with which it co-occurs termed the cgr-associated gene cluster (18) (Supplement…”
BackgroundMethodInfluentialSelf-citationA new evaluation system for drug–microbiota interactions
Liu, T., Zhang, C., Zhang, H., Jin, J., Li, X., Liang, S., Xue, Y., Yuan, F., Zhou, Y., Bian, X., et al. (2024) · iMeta · doi:10.1002/imt2.199 · Cited by 19
Tutorial: Microbiome studies in drug metabolism
Dodd, D., & Cann, I. (2022) · Clinical and Translational Science · doi:10.1111/cts.13416 · Cited by 17
Gut microbiota: what is its place in pharmacology?
Tarasiuk, A., & Fichna, J. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1670058 · Cited by 17
Chen, J., Mao, Y., Xing, C., Hu, R., Xu, Z., Cao, H., & Luo, J. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/3647525 · Cited by 16
Mohammadi, S., Yang, L., Bulbert, M., & Rowland, H. M. (2022) · Royal Society Open Science · doi:10.1098/rsos.220363 · Cited by 17
A mechanism-based understanding of altered drug pharmacokinetics by gut microbiota
Gulnaz, A., Chang, J., Maeng, H., Shin, K., Lee, K., & Chae, Y. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00600-z · Cited by 18
Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease
Zhang, Y., Mo, C., Ai, P., He, X., Xiao, Q., & Yang, X. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2454937 · Cited by 20
Pharmacometabolomics Informs Viromics toward Precision Medicine
Balasopoulou, A., Patrinos, G. P., & Κάτσιλα, Θ. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00411 · Cited by 18
Precarious Symbiosis Between Host and Microbiome in Cardiovascular Health
Bartolomaeus, H., Markó, L., Wilck, N., Luft, F. C., Forslund, S. K., & Müller, D. N. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.11786 · Cited by 19
Darm-Herz-Achse: Wie Darmbakterien kardiovaskuläre Erkrankungen beeinflussen
Bartolomaeus, H., McParland, V. J., & Wilck, N. (2020) · Herz · doi:10.1007/s00059-020-04897-0 · Cited by 23
Approaching precision medicine by tailoring the microbiota
Ryu, G., Kim, H., & Koh, A. (2021) · Mammalian Genome · doi:10.1007/s00335-021-09859-3 · Cited by 17
The Central Role of Gut Microbiota in Drug Metabolism and Personalized Medicine
Colotti, G., & Rinaldi, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0023 · Cited by 19
“Drug bioavailability can be affected by gut microbiota: the cardiac glycoside digoxin is reduced to metabolites such as dihydrodigoxin and thereby inactivated by reducing strains of Eggerthella lenta [20].”
BackgroundSater, A. H. A., Bouferraa, Y., Amhaz, G., Haibe, Y., Lakkiss, A. E., & Shamseddine, A. I. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.804983 · Cited by 17
Yang, H., Zhang, Y., Zhou, R., Wu, T., Zhu, P., Liu, Y., Zhou, J. W., Xiong, Y., Xiong, Y., Zhou, H.-H., et al. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.001173 · Cited by 15
In-silico computational approaches to study microbiota impacts on diseases and pharmacotherapy
Garjan, H. S., Omidi, Y., Asghari, M. P., & Ferdousi, R. (2023) · Gut Pathogens · doi:10.1186/s13099-023-00535-2 · Cited by 18
“GIT microbes also play an important role as a therapeutic target in precision medicine and modulation of drug activity or toxicity [36], while their diversity and function can be altered by drugs [37].”
BackgroundInteraction of drugs with gut microbiota modulators
Kim, D. (2023) · Drug Metabolism Reviews · doi:10.1080/03602532.2023.2197178 · Cited by 15
“Reduction and deglycosylation of drugs by gut microbiota Orally administered digoxin is converted to the inactive metabolites dihydrodigoxin and dihydrodigoxigenin in some patients by gut microbiota reductase and/or b-Ddigitoxosidase (Dobkin et al. 1982; Haiser et al. 2013).”
BackgroundInfluentialZaidi, S., Ali, K., & Khan, A. U. (2023) · Archives of Microbiology · doi:10.1007/s00203-023-03589-7 · Cited by 16
Effect of Gut Microbiota on the Pharmacokinetics of Nifedipine in Spontaneously Hypertensive Rats
Zhou, R., Yang, H., Zhu, P., Liu, Y., Zhang, Y., Zhang, W., Zhou, H., Li, X., & Li, Q. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082085 · Cited by 15
“Eggerthella lenta can reduce digoxin in vitro, and pharmacokinetic studies in vivo revealed that diet could reduce the microbial metabolism of digoxin [10].”
BackgroundOperomeDB: A Database of Condition-Specific Transcription Units in Prokaryotic Genomes
Chetal, K., & Janga, S. C. (2015) · BioMed Research International · doi:10.1155/2015/318217 · Cited by 17
“In prokaryotic organisms, a substantial fraction of adjacent genes are organized into operons—codirectionally organized genes in prokaryotic genomes with the presence of a common promoter and terminator.”
BackgroundCong, J., Zhu, J., Zhang, C., Li, T., Liu, K., Liu, D., Zhou, N., Jiang, M., Hou, H., & Zhang, X. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01008 · Cited by 16
“implicated intestinal microbiota at the species level in influencing the drug response and toxicity of CRC patients (Haiser et al., 2013).”
BackgroundButtimer, C., Bottacini, F., Shkoporov, A. N., Draper, L. A., Ross, R. P., & Hill, C. (2022) · Microorganisms · doi:10.3390/microorganisms10010195 · Cited by 17
“lenta strains vary in their capacity to act on digoxin and lignans [12].”
BackgroundGut Microbiota as the Potential Mechanism to Mediate Drug Metabolism Under High-altitude Hypoxia
Bai, X., Liu, G., Yang, J., Zhu, J., & Li, X. (2022) · Current Drug Metabolism · doi:10.2174/1389200223666220128141038 · Cited by 15
Bacteria-Mediated Modulatory Strategies for Colorectal Cancer Treatment
Mueller, A., Brockmueller, A., Fahimi, N., Ghotbi, T., Hashemi, S., Sadri, S., Khorshidi, N., Kunnumakkara, A. B., & Shakibaei, M. (2022) · Biomedicines · doi:10.3390/biomedicines10040832 · Cited by 17
Xu, L., Li, X., Zhang, E., Liang, H., Li, W., Wang, S., Song, S., & Ji, A. (2018) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2018.1465076 · Cited by 15
“found that intestinal bacteria can cause inactivation of digoxin drugs (34).”
BackgroundBastard, Q. L., Chevallier, P., & Montassier, E. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i45.7792 · Cited by 15
Pedersen, K. J., Haange, S., Žížalová, K., Viehof, A., Clavel, T., Leníček, M., Engelmann, B., Wick, L. Y., Schaap, F. G., Jehmlich, N., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10102025 · Cited by 17
PARASKEVAIDIS, I. A., Briasoulis, Α., & Tsougos, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031716 · Cited by 17
“…can be converted by Eggerthella lenta into an inactive metabolite in a substantial number of patients (10%), thus limiting the amount of drug reaching the target tissue [82], whereas an arginine-rich diet demonstrates the drug–blood fluctuation of this specific drug [83], thus limiting its action.”
BackgroundGut bacteria: an etiological agent in human pathological conditions
Islam, M. M., Mahbub, N. U., Hong, S., & Chung, H. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1291148 · Cited by 18
Heart Failure and Gut Microbiota: What Is Cause and Effect?
Shen, S., Tian, B., Haizhu, Z., Wang, Y., Li, T., & Cao, Y. (2025) · Research · doi:10.34133/research.0610 · Cited by 20
“For instance, Eggerthella lenta can inactivate digoxin, a commonly used heart medication [ 48 ].”
Metadata
- Authors
- Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Turnbaugh, Peter J.
- Venue
- Science
- Published
- 2013-07-19
- Volume
- 341
- Issue
- 6143
- Pages
- 295-298
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3736355
- OpenAlex
- W2161185495
- Cited by
- 704
- References
- 25
- Citations by year
- 2026: 66 · 2025: 58 · 2024: 64 · 2023: 65 · 2022: 54 · 2021: 59 · 2020: 77 · 2019: 56 · 2018: 56 · 2017: 41 · 2016: 31 · 2015: 31 · 2014: 38 · 2013: 8
- FWCI
- 39.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (112991_1)
- National Institute of General Medical Sciences (P50GM068763)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034854)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Eggerthella lenta, digoxin, drug inactivation, gut microbiota, cytochrome P450, gnotobiotic mice, dietary protein, pharmacokinetics, cardiovascular drugs, human-microbe interactions
- MeSH terms
- Animals, Arginine, Cytochromes, Dietary Proteins, Digoxin, Feces, Germ-Free Life, Humans, Mice, Inbred Strains, Operon, Gene Expression Regulation, Bacterial, Actinobacteria, Gastrointestinal Tract, Mice, Metagenome, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.